Physician profile
Dan Ilkovitch
NPI 1447512827
$9,770.49
in general payments reported to CMS, 2019-2025
30 companies · $2,127 in 2025
The $2,127 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $353 · 2021: $832 · 2022: $1,453 · 2023: $1,672 · 2024: $2,189 · 2025: $2,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,530 · Education: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,530.09 |
| Education | $457.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,733.62 | 2019-2025 | |
| Janssen Biotech, INC. | $1,486.30 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $1,358.05 | 2019-2025 | |
| Galderma Laboratories, L.P. | $684.90 | 2019-2025 | Nemluvio, Oracea, Aklief |
| Sun Pharmaceutical Industries INC. | $621.93 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $588.30 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $524.44 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $483.14 | 2019-2025 | |
| Pfizer INC. | $283.06 | 2019-2025 | |
| Ucb, INC. | $254.74 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $245.38 | 2022-2024 | Sotyktu |
| Incyte Corporation | $177.49 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $174.76 | 2019-2024 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $122.88 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.54 | 2019-2024 | Jublia, Arazlo, Cabtreo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.31 | 2022-2025 | Spevigo |
| Leo Pharma INC. | $110.37 | 2022-2025 | Adbry, Spevigo |
| Organon LLC | $108.57 | 2025 | |
| Arcutis Biotherapeutics, INC. | $84.59 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $80.33 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $59.69 | 2024 | Daxxify |
| Biofrontera INC. | $57.08 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $50.90 | 2024 | Ycanth |
| Almirall LLC | $46.16 | 2021 | |
| Botanix Sb INC | $43.94 | 2025 | Sofdra |
| Celgene Corporation | $41.53 | 2019 | |
| Paratek Pharmaceuticals, INC. | $36.29 | 2022-2023 | Nuzyra |
| Merz North America, INC. | $33.54 | 2023 | Xeomin |
| Journey Medical Corporation | $21.59 | 2023 | |
| Nabriva Therapeutics, Plc | $21.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Ilkovitch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.